PedAM
Pediatric Disease Annotations & Medicines
| Disease | adenocarcinoma |
| Phenotype | C0007131|nsclc |
| Sentences | 43 |
| PubMedID- 22748043 | Non-small cell lung cancers (nsclc), including adenocarcinoma, squamous and large-cell tumors, represent 85 % of all lung tumors and result in 1.9 million deaths each year [1]. |
| PubMedID- 24040454 | Egfr mutations were frequently present in female patients (72 of 113, 63.7%) and nsclc with adenocarcinoma component (125/204, 61.3%) with statistical significance. |
| PubMedID- 21165163 | Egfr mutations are more common in nsclc from tumors with adenocarcinoma histology, women, asians, and never smokers with widely varying frequencies dependent on the population examined [26-28]. |
| PubMedID- 23961259 | There has been an increasing trend of diagnosis of nsclc with adenocarcinoma histology in never smoker group, world-wide and in india as well. |
| PubMedID- 22890830 | The results indicate that the serum level of cea was higher in nsclc patients with adenocarcinoma relative to those with squamous cell carcinoma, but no significant differences in the other serum markers. |
| PubMedID- 26521535 | Also reviewed are the current standards of care and trends in the molecular testing of nsclc with adenocarcinoma features and possible future molecular targets. |
| PubMedID- 24711160 | Interestingly, there appear to be some fgf/fgfr signaling pathway-related distinctions between nsclc cases of squamous cell versus adenocarcinoma histology 15–17,33,34. |
| PubMedID- 24758269 | 85% of lung cancer is non-small cell lung cancer (nsclc), with adenocarcinoma (ad) and squamous cell carcinoma (scc) as the two major pathological subtypes [1]. |
| PubMedID- 22992338 | Kras and egfr play pivotal roles in the development and growth of nsclc, especially in patients with adenocarcinoma histology. |
| PubMedID- 23284758 | Immunohistochemical (ihc) staining was carried out using tissue microarrays purchased from shanghai outdo biotech co.. in brief, formalin-fixed, paraffin-embedded sections from 90 nsclc patients, consisting of 44 lung adenocarcinoma (ad), 38 squamous cell carcinoma (scc), and 8 cases of other subtypes, were deparaffinized and rehydrated. |
| PubMedID- 20843324 | The ipass study suggested that gefitinib would be efficacious in first-line treatment of locally advanced or metastatic nsclc patients with adenocarcinoma who have never or seldom smoked [13]. |
| PubMedID- 21989766 | Four patients on the cdd nsclc expansion cohort, with histologies of adenocarcinoma (n = 2) and large cell carcinoma (n = 2), also had prs. |
| PubMedID- 23190601 | About 70-80% of lung carcinomas fall under the classification of nsclc with adenocarcinoma as the most common subtype[22]. |
| PubMedID- 24955213 | Approximately 85% are non-small cell lung cancers (nsclc), consisting mainly of squamous cell, adenocarcinoma, adenosquamous carcinoma, and large-cell anaplastic carcinoma, with most being adenocarcinomas [2,3]. |
| PubMedID- 23082117 | nsclc is composed of three different subtypes: adenocarcinoma (adc), squamous cell carcinoma (scc), and large cell carcinoma (lcl). |
| PubMedID- 22024187 | We analyzed the prognostic value of galectin-3 expression in all patients with nsclc and separately in patients with scc and adenocarcinoma, and separately in every stage, but we didn't find any statistical significant differences (table 1 and figure 2). |
| PubMedID- 25257766 | Kras mutations are the most common mutations in non-small cell lung cancer (nsclc) with adenocarcinoma histology. |
| PubMedID- 21540238 | Inhibitor of differentiation-1 as a novel prognostic factor in nsclc patients with adenocarcinoma histology and its potential contribution to therapy resistance. |
| PubMedID- 26448936 | According to the international cancer advocacy network (ican) study (nct01106781) investigating egfr gene mutation status in early-stage chinese nsclc patients with adenocarcinoma (adc) histology, 55.1% patients were egfr mutation positive [89]. |
| PubMedID- 25436007 | K-ras and egfr mutations were mutually exclusive (p=0.0006), observed only in the nsclc patients with adenocarcinoma (p<0.0001). |
| PubMedID- 26493267 | Exclusion criteria included tumors harboring egfr mutation, prior systemic chemotherapy for nsclc, non-smoking patients with adenocarcinoma (except patients with wild-type egfr), symptomatic brain metastasis and any unstable medical condition. |
| PubMedID- 24376508 | Study cohort a consisted of surgically resected or biopsy nsclc samples enriched with adenocarcinoma histology. |
| PubMedID- 26316940 | Analyzed 1457 nsclc samples of either adenocarcinoma (ac) or squamous cell carcinoma (scc) for mrna expression levels of ts, ercc1, and rrm1 [42]. |
| PubMedID- 25692143 | Lung cancer is the leading cause of cancer-related death worldwide [1, 2], and approximately 80% of cases of lung cancer are non-small cell lung cancer (nsclc) [1], with lung adenocarcinoma (lac) being the most prevalent type. |
| PubMedID- 25036876 | For nsclc patients with non-adenocarcinoma histology, bcl-2 expression was associated with increased overall survival (p = 0.036). |
| PubMedID- 26247735 | Lcscs from wt-egfr nsclc patients with scc (n=3), adenocarcinoma (adc, n=3) and large-cell neuroendocrine carcinoma (lcnec, n=1; table 1a) were isolated as tumor spheres in serum-free culture conditions that enrich cultures for undifferentiated tumor cells endowed with stem cell properties of long-term proliferation capacity, increased clonogenic potential, differentiation ability, chemoresistance, increased tumorigenicity and ability to generate xenografts that mimic the tumor of origin, as we previously reported24, 32, 33 and have shown in figure 1. functional response of lcsc to erlotinib over 2-day in vitro exposure was then assessed in comparison with standard chemotherapy: cisplatin, gemcitabine, pemetrexed for adc-derived lcsc, cisplatin, gemcitabine, docetaxel for scc-derived lcsc and cisplatin, etoposide, gemcitabine or docetaxel for lcnec-derived lcscs. |
| PubMedID- 24260109 | About 80% of lung cancers (lc), the leading cause of cancer-related death throughout the world, are classified as non-small cell lung carcinoma (nsclc) with adenocarcinoma (ac) and squamous cell carcinoma (scc) the two major subtypes of nsclc. |
| PubMedID- 25031935 | While this gene rearragement is uncommon, the test for eml4-alk should be considered for all nsclc patients with adenocarcinoma histology who have adequate tissue for sampling. |
| PubMedID- 24744457 | nsclc tumors consist mainly of three subtypes: adenocarcinoma (40% of lung cancers), squamous cell carcinoma (25% of lung cancers), and large cell carcinoma (10% of lung cancers). |
| PubMedID- 24885564 | Background: although many of the recently approved genomically targeted therapies have improved outcomes for patients in non-small-cell lung cancer (nsclc) with lung adenocarcinoma, little is known about the genomic alterations that drive lung squamous cell cancer (scc) and development of effective targeted therapies in lung scc is a promising area to be further investigated. |
| PubMedID- 25929582 | Non–small-cell lung cancer (nsclc), a heterogeneous group of histologies that includes adenocarcinoma, squamous cell carcinoma and large cell carcinoma, accounts for approximately 85% of all lung cancers [1]. |
| PubMedID- 23936861 | A randomized, double-blind phase iii study of motesanib plus carboplatin/paclitaxel in 1090 patients (of those, 890 had adenocarcinoma) with advanced nsclc demonstrated the combination did not significantly improve os over carboplatin/paclitaxel alone, with a median os of 13 months and 11 months and median pfs of 5.6 months and 5.4 months for carboplatin/paclitaxel plus motesanib and carboplatin/paclitaxel alone, respectively [50]. |
| PubMedID- 24743704 | We also observed that egfr e19/e21 mutations were significantly higher in nsclc from tumours with adenocarcinoma histology (43.6% vs 8.5%, p⩽0.001), in women (51.5% vs 23.5%, p⩽0.001) and in never smokers (51.0% vs 18.1%, p⩽0.001), which are similar to results of previous reports (xu et al, 2011; dogan et al, 2012). |
| PubMedID- 20849603 | Six nsclc cell lines consisting of three adenocarcinoma cell lines (a549, h522 and h358), two large carcinoma cell lines (h460, h661), and one squamous cell carcinoma cell line (h226), as well as one small cell lung cancer cell line (sclc) (h841) were obtained from the american type culture collection (rockville, md, us), grown in rpmi-1640 medium (sigma) supplemented with 10% fetal bovine serum, and collected under standard tissue culture protocols. |
| PubMedID- 23423768 | The two most common are: 1) short in-frame deletions around the lrea motif of exon 19 (~45-50% of mutations); and 2) a point mutation (ctg to cgg) in exon 21 that results in substitution of leucine by arginine at codon 858, l858r (~45-50% of mutations)14,15. these mutations are more frequently found in nsclc with an adenocarcinoma histology, tumors in women, east asians and never smokers14-16. |
| PubMedID- 25737737 | Non-small-cell lung cancer (nsclc), including adenocarcinoma, squamous cell carcinoma, and large-cell carcinoma, accounts for ~80% of all lung cancers [3] and requires surgical removal as the sole curative therapy which yet could be considered only in a limited proportion of patients at still early disease stages [2]. |
| PubMedID- 24304694 | We analyzed sec62 levels in cancerous and tumor-free lung tissue from 70 non-small cell lung cancer (nsclc) patients with pathologically confirmed adenocarcinoma (ac) or squamous cell carcinoma (scc) using western blot with β-actin as a loading control. |
| PubMedID- 24661338 | Non-small cell lung cancer (nsclc), including adenocarcinoma (ad) and squamous cell carcinoma (sc), is the leading cause of cancer death in both men and women in the united states [1]. |
| PubMedID- 21129810 | Methods: records of 592 consecutive asian patients with primary nsclc (excluding adenocarcinoma in situ) who had, without any preoperative therapy, undergone lobectomy, sleeve lobectomy and pneumonectomy were examined. |
| PubMedID- 23110967 | Some reports suggest that adenocarcinoma patients with stage i nsclc tend to have a better survival[14]. |
| PubMedID- 25944691 | 37.65 months, p = 0.045) only in nsclc patients with adenocarcinoma (adc). |
| PubMedID- 24085278 | Among nsclc, patients with squamous, adenocarcinoma or squamous adenocarcinoma lung cancer also undergo diverse clinical chemotherapy combination. |
| PubMedID- 22572014 | Egfr mutations are more common in chinese nsclc patients with adenocarcinoma histology and non-smoking status. |
Page: 1